Ancillary Tools for the Diagnosis of CIC ‐Rearranged Sarcoma: A Comprehensive Review
Journal of Cutaneous Pathology · 2025-04 · 52 (4) · 324-331
DOI: 10.1111/cup.14792 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cutaneous Pathology, online erschienen am 08.02.2025. Verfasst von Jeffrey M Cloutier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA. Hauptthemen laut MEDLINE: Sarcoma, Gene Rearrangement, Biomarkers, Tumor, Repressor Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
CIC ‐rearranged sarcoma is a rare and aggressive undifferentiated round cell sarcoma that presents significant diagnostic challenges due to its histologic overlap with other round cell sarcomas. This review, conducted on behalf of the American Society of Dermatopathology Appropriate Use Criteria Committee (soft tissue subgroup), provides an overview of current immunohistochemical, cytogenetic, and molecular tests used to support the diagnosis of CIC ‐rearranged sarcoma. This comprehensive analysis included 36 studies, encompassing 436 CIC ‐rearranged sarcomas. The immunohistochemical markers, CD99 (typically non‐diffuse), nuclear WT1, ETV4, and DUX4, were found to be relatively highly sensitive for CIC ‐rearranged sarcoma (CD99: 87%, WT1: 83%, ETV4: 85%, DUX4: 97%). However, the specificity of these markers is variable, with CD99 being highly non‐specific, while WT1 (81%–90%), ETV4 (95%), and DUX4 (100%) offering greater specificity. CIC break‐apart FISH can be a helpful and cost‐effective assay for detection of CIC ‐rearrangements, but has a false‐negative rate that ranges from 26% to 43%. Next‐generation sequence RNA fusion analysis also carries a risk of false negatives, which may be partly mitigated through manual data review. Ultimately, an accurate diagnosis of CIC ‐rearranged sarcoma requires careful morphologic assessment in combination with immunohistochemical studies and cytogenetics/molecular assays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.
- Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
- Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
- WCP Laboratories, Maryland Heights, St. Louis, Missouri, USA.
- Department of Pathology, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, Manhattan, New York, USA.
ORCID-Profile: Jeffrey M Cloutier, Jennifer S Ko, Konstantinos Linos
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Cloutier, J. M., Al-Rohil, R. N., Patel, R. M., Ko, J. S., & Linos, K. (2025). Ancillary Tools for the Diagnosis of CIC ‐Rearranged Sarcoma: A Comprehensive Review. Journal of Cutaneous Pathology, 52(4), 324-331. https://doi.org/10.1111/cup.14792
Vancouver
Cloutier JM, Al-Rohil RN, Patel RM, Ko JS, Linos K. Ancillary Tools for the Diagnosis of CIC ‐Rearranged Sarcoma: A Comprehensive Review. Journal of Cutaneous Pathology. 2025;52(4):324-331. doi:10.1111/cup.14792
BibTeX
@article{Cloutier2025,
author = {Cloutier, Jeffrey M and Al-Rohil, Rami N and Patel, Rajiv M and Ko, Jennifer S and Linos, Konstantinos},
title = {Ancillary Tools for the Diagnosis of CIC ‐Rearranged Sarcoma: A Comprehensive Review},
journal = {Journal of Cutaneous Pathology},
year = {2025},
volume = {52},
number = {4},
pages = {324--331},
doi = {10.1111/cup.14792}
}
EUVIMED